MFS
BMRN icon

Monetta Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Monetta Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,000
Closed -$623K – 92
2015
Q1 		$623K Buy
+5,000
New +$530K 0.33% 58

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Monetta Financial Services's BMRN Position: Q2 2015 in Review

Monetta Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 5,000 shares — an estimated $623K sold.

Monetta Financial Services first reported a position in BMRN in Q1 2015 and held it in 1 quarter. The position peaked at $623K in Q1 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

  • Monetta Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Monetta Financial Services sold 5,000 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $623K.
  • Monetta Financial Services first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Monetta Financial Services's BioMarin Pharmaceuticals position peaked at $623K in Q1 2015.
  • 391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Monetta Financial Services's 13F filing for Q2 2015, filed 5 Aug 2015.